

Eli Muchtar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8239160/publications.pdf>

Version: 2024-02-01

292
papers

4,643
citations

136740

32
h-index

149479

56
g-index

297
all docs

297
docs citations

297
times ranked

5194
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Outcomes after biochemical or clinical progression in patients with multiple myeloma. <i>Blood Advances</i> , 2023, 7, 909-917. | 2.5 | 7 |
| 2 | Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€“Associated Lesions: A Case Series. <i>American Journal of Kidney Diseases</i> , 2022, 79, 202-216. | 2.1 | 9 |
| 3 | Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808. | 3.3 | 43 |
| 4 | Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2022, 36, 873-876. | 3.3 | 12 |
| 5 | Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2022, 97, 90-98. | 2.0 | 13 |
| 6 | Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2022, 36, 1058-1065. | 3.3 | 3 |
| 7 | Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215. | 2.0 | 5 |
| 8 | Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. <i>Leukemia</i> , 2022, 36, 1426-1428. | 3.3 | 7 |
| 9 | Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , . | 2.0 | 2 |
| 10 | Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . <i>Leukemia</i> , 2022, 36, 1429-1431. | 3.3 | 8 |
| 11 | Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. <i>Blood Advances</i> , 2022, , . | 2.5 | 11 |
| 12 | Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2022, , . | 1.3 | 0 |
| 13 | Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59. | 2.8 | 3 |
| 14 | Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 2422-2427. | 0.6 | 2 |
| 15 | Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40. | 0.2 | 1 |
| 16 | Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM. <i>Cancer Research</i> , 2022, 82, CT186-CT186. | 0.4 | 2 |
| 17 | Impact of belantamab mafodotinâ€“induced ocular toxicity on outcomes of patients with advanced multiple myeloma. <i>British Journal of Haematology</i> , 2022, 199, 95-99. | 1.2 | 14 |
| 18 | Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. <i>Blood Advances</i> , 2022, 6, 5429-5435. | 2.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 199, 239-244. | 1.2 | 9 |
| 20 | Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021, 100, 143-155. | 0.8 | 32 |
| 21 | Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277. | 1.3 | 1 |
| 22 | A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715. | 2.6 | 13 |
| 23 | Outcomes of multiple myeloma patients with $\text{del } 17p$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38. | 2.0 | 2 |
| 24 | Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361. | 1.1 | 4 |
| 25 | Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021, 106, 433-436. | 1.1 | 3 |
| 26 | Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150. | 1.3 | 15 |
| 27 | Implications of detecting serum monoclonal protein by MASSfix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385. | 1.2 | 21 |
| 28 | Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 928-935. | 1.3 | 5 |
| 29 | Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5. | 0.6 | 1 |
| 30 | Novel imaging techniques using ^{18}F -florbetapir PET/MRI can guide fascicular nerve biopsy in amyloid multiple mononeuropathy. <i>Muscle and Nerve</i> , 2021, 63, 104-108. | 1.0 | 3 |
| 31 | Systemic amyloidosis from A (AA) to T (ATTR): a review. <i>Journal of Internal Medicine</i> , 2021, 289, 268-292. | 2.7 | 133 |
| 32 | Amyloid arthropathy in smoldering myeloma: Do not take it lightly. <i>Leukemia Research Reports</i> , 2021, 15, 100242. | 0.2 | 2 |
| 33 | Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437. | 3.3 | 8 |
| 34 | Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021, 5, 1029-1036. | 2.5 | 9 |
| 35 | Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387. | 1.4 | 12 |
| 36 | Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 47. | 2.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687. | 1.4 | 16 |
| 38 | MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50. | 2.8 | 25 |
| 39 | The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021, 138, 149-159. | 0.6 | 20 |
| 40 | The prognostic significance of $\langle \text{scp} \rangle \text{del}6q23 \langle / \text{scp} \rangle$ in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E203-E206. | 2.0 | 1 |
| 41 | Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 355-360. | 0.2 | 5 |
| 42 | Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607. | 3.3 | 8 |
| 43 | Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021, 11, 86. | 2.8 | 14 |
| 44 | Assessment of fixed-duration therapies for treatment-naïve $\langle \text{scp} \rangle \text{Waldenström} \langle / \text{scp} \rangle$ macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953. | 2.0 | 12 |
| 45 | Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577. | 1.4 | 32 |
| 46 | The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2. | 0.2 | 9 |
| 47 | Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6. | 0.6 | 3 |
| 48 | 67-Year-Old Man With Fatigue, Lightheadedness, and Erythrocytosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1949-1954. | 1.4 | 0 |
| 49 | Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018. | 0.6 | 2 |
| 50 | Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136. | 2.0 | 21 |
| 51 | Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021, 11, 140. | 2.8 | 6 |
| 52 | CLL-376: Clinical Characteristics and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL), 80 Years of Age or Older. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S324-S325. | 0.2 | 0 |
| 53 | The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, 158. | 2.8 | 9 |
| 54 | The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. American Journal of Hematology, 2021, 96, 446-454. | 2.0 | 8 |
| 56 | Monitoring Tafamidis, The Most Expensive Cardiac Medication. JACC: CardioOncology, 2021, 3, 587-589. | 1.7 | 0 |
| 57 | Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , . | 2.0 | 6 |
| 58 | OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S23-S24. | 0.2 | 0 |
| 59 | "Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639. | 0.6 | 3 |
| 60 | Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. Blood, 2021, 138, 2707-2707. | 0.6 | 0 |
| 61 | An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN γ -NIS). Blood, 2021, 138, 1333-1333. | 0.6 | 0 |
| 62 | Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700. | 0.6 | 0 |
| 63 | Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio \geq 100. Blood, 2021, 138, 1617-1617. | 0.6 | 0 |
| 64 | Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720. | 0.6 | 4 |
| 65 | Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819. | 0.6 | 1 |
| 66 | Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805. | 0.6 | 0 |
| 67 | A Phase 1 Study of CFT7455, a Novel Degradar of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma. Blood, 2021, 138, 1675-1675. | 0.6 | 8 |
| 68 | Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186. | 2.8 | 8 |
| 69 | Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760. | 0.6 | 1 |
| 70 | Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721. | 0.6 | 5 |
| 71 | Prognostic Factors for Early (≤ 2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761. | 0.6 | 0 |
| 72 | Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The Role of Non-Coding RNAs in the Pathogenesis of AL Amyloidosis. <i>Blood</i> , 2021, 138, 2659-2659. | 0.6 | 0 |
| 74 | Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory). <i>Blood</i> , 2021, 138, 1560-1560. | 0.6 | 0 |
| 75 | The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1619-1619. | 0.6 | 0 |
| 76 | Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021, 138, 543-543. | 0.6 | 0 |
| 77 | Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021, 138, 1630-1630. | 0.6 | 0 |
| 78 | Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021, 138, 119-119. | 0.6 | 0 |
| 79 | The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021, 138, 2650-2650. | 0.6 | 0 |
| 80 | Early intervention in asymptomatic chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 92-103. | 0.3 | 6 |
| 81 | “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196. | 2.8 | 28 |
| 82 | Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020, 105, 765-773. | 1.7 | 64 |
| 83 | Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16. | 1.4 | 25 |
| 84 | New developments in diagnosis, risk assessment and management in systemic amyloidosis. <i>Blood Reviews</i> , 2020, 40, 100636. | 2.8 | 28 |
| 85 | Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403. | 1.2 | 41 |
| 86 | Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10. | 2.0 | 10 |
| 87 | Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9. | 2.0 | 14 |
| 88 | Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56. | 0.2 | 8 |
| 89 | Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315. | 2.0 | 37 |
| 90 | The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 384-395. | 0.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281. | 2.0 | 33 |
| 92 | IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382. | 3.3 | 40 |
| 93 | Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020, 34, 1472-1475. | 3.3 | 15 |
| 94 | Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143. | 3.3 | 29 |
| 95 | Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020, 95, E57-E60. | 2.0 | 9 |
| 96 | Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980. | 1.9 | 15 |
| 97 | Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901. | 1.3 | 3 |
| 98 | Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979. | 0.6 | 2 |
| 99 | Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287. | 2.0 | 17 |
| 100 | Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124. | 2.8 | 12 |
| 101 | The Clinical Implication of Incidental Prostatic Amyloidosis. <i>Urology</i> , 2020, 145, 253-257. | 0.5 | 7 |
| 102 | Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137. | 1.3 | 8 |
| 103 | Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405. | 2.0 | 4 |
| 104 | The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52. | 2.8 | 8 |
| 105 | Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55. | 2.8 | 36 |
| 106 | Updates in the Diagnosis and Management of AL Amyloidosis. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 155-167. | 1.2 | 10 |
| 107 | Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 944-954. | 1.4 | 7 |
| 108 | The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020, 9, 3390-3399. | 1.3 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 1752-1755. | 0.6 | 5 |
| 110 | Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642. | 2.0 | 12 |
| 111 | Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20. | 2.8 | 26 |
| 112 | The Impact of Proliferating Polyclonal Plasma Cells on Outcome after Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S239. | 2.0 | 0 |
| 113 | Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4. | 2.8 | 18 |
| 114 | Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502. | 2.0 | 35 |
| 115 | Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. <i>American Journal of Hematology</i> , 2020, 95, E222-E225. | 2.0 | 15 |
| 116 | Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601. | 0.2 | 15 |
| 117 | Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 322-326. | 2.5 | 8 |
| 118 | Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388. | 0.6 | 15 |
| 119 | Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020, 136, 39-40. | 0.6 | 1 |
| 120 | Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 52-53. | 0.6 | 4 |
| 121 | MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49. | 0.6 | 2 |
| 122 | Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37. | 0.6 | 4 |
| 123 | Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 22-23. | 0.6 | 1 |
| 124 | The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020, 105, 2675-2678. | 1.7 | 17 |
| 125 | Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8516-8516. | 0.8 | 0 |
| 126 | Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8549-8549. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. Journal of Clinical Oncology, 2020, 38, e20515-e20515. | 0.8 | 0 |
| 128 | The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10. | 0.6 | 0 |
| 129 | Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. Blood, 2020, 136, 26-27. | 0.6 | 0 |
| 130 | A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45. | 0.6 | 0 |
| 131 | Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. Blood, 2020, 136, 3-4. | 0.6 | 1 |
| 132 | Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-13. | 0.6 | 0 |
| 133 | Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15. | 0.6 | 0 |
| 134 | Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7. | 0.6 | 0 |
| 135 | Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22. | 0.6 | 0 |
| 136 | Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13. | 0.6 | 0 |
| 137 | Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 16-17. | 0.6 | 1 |
| 138 | Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2. | 0.6 | 0 |
| 139 | Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42. | 0.6 | 0 |
| 140 | Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 49-50. | 0.6 | 1 |
| 141 | Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 50-51. | 0.6 | 7 |
| 142 | Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447. | 1.3 | 7 |
| 143 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367. | 1.3 | 81 |
| 144 | Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594. | 1.2 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102. | 1.4 | 9 |
| 146 | Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019, 3, 1226-1229. | 2.5 | 7 |
| 147 | Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026. | 2.0 | 36 |
| 148 | Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071. | 2.0 | 14 |
| 149 | Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814. | 3.3 | 22 |
| 150 | The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050. | 1.3 | 9 |
| 151 | Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525. | 2.0 | 9 |
| 152 | Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2712-2719. | 0.6 | 42 |
| 153 | The colorful landscape of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2099-2100. | 0.6 | 1 |
| 154 | Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CAMEL). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S30. | 2.0 | 2 |
| 155 | Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272. | 3.3 | 7 |
| 156 | Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143. | 2.0 | 17 |
| 157 | A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483. | 1.4 | 59 |
| 158 | Venetoclax for the Treatment of Multiple Myeloma: Outcomes Outside of Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e278-e279. | 0.2 | 0 |
| 159 | Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e305. | 0.2 | 0 |
| 160 | Impact of Minimal Residual Negativity on Outcomes in Light Chain Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e331-e332. | 0.2 | 0 |
| 161 | Blood mass spectrometry Detects Residual Disease Better than Standard Techniques in Immunoglobulin light chain amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e313. | 0.2 | 1 |
| 162 | The role of bone marrow biopsy in patients with plasma cell disorders; should all patients with a monoclonal protein be biopsied?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e333. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | A Hematopoietic Score Predicts Survival in Newly Diagnosed Multiple Myeloma Patients.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e85-e86. | 0.2 | 0 |
| 164 | PF385 ANTICOAGULATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB. HemaSphere, 2019, 3, 144-145. | 1.2 | 1 |
| 165 | Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e301-e302. | 0.2 | 0 |
| 166 | Venetoclax For The Treatment of Translocation AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e332. | 0.2 | 1 |
| 167 | Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood, 2019, 133, 763-766. | 0.6 | 27 |
| 168 | <i>IGH</i> translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. American Journal of Hematology, 2019, 94, 338-345. | 2.0 | 19 |
| 169 | Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081. | 1.3 | 7 |
| 170 | Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794. | 3.3 | 28 |
| 171 | Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531. | 3.3 | 36 |
| 172 | Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019, 33, 531-536. | 3.3 | 72 |
| 173 | Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. Blood, 2019, 134, 3510-3510. | 0.6 | 1 |
| 174 | A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2019, 134, 4306-4306. | 0.6 | 3 |
| 175 | BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. Blood, 2019, 134, 3050-3050. | 0.6 | 3 |
| 176 | Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334. | 0.6 | 1 |
| 177 | Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386. | 0.6 | 2 |
| 178 | Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 864-864. | 0.6 | 13 |
| 179 | Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905. | 0.6 | 2 |
| 180 | Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes.. Journal of Clinical Oncology, 2019, 37, 7522-7522. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. Journal of Clinical Oncology, 2019, 37, 8039-8039. | 0.8 | 31 |
| 182 | Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.. Journal of Clinical Oncology, 2019, 37, e19519-e19519. | 0.8 | 2 |
| 183 | Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464. | 1.4 | 16 |
| 184 | PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. HemaSphere, 2019, 3, 641-642. | 1.2 | 0 |
| 185 | PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). HemaSphere, 2019, 3, 527-528. | 1.2 | 1 |
| 186 | Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. Blood, 2019, 134, 4505-4505. | 0.6 | 0 |
| 187 | Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523. | 0.6 | 0 |
| 188 | Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532. | 0.6 | 0 |
| 189 | Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080. | 0.6 | 0 |
| 190 | Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833. | 0.6 | 0 |
| 191 | Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532. | 0.6 | 0 |
| 192 | The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. Blood, 2019, 134, 3037-3037. | 0.6 | 0 |
| 193 | Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171. | 0.6 | 1 |
| 194 | The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197. | 0.6 | 0 |
| 195 | Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490. | 0.6 | 1 |
| 196 | Outcomes of Autologous Hematopoietic Stem Cell Transplant in Sporadic Late Onset Nemaline Myopathy with Associated Monoclonal Gammopathy of Unknown Significance. Biology of Blood and Marrow Transplantation, 2018, 24, S124-S125. | 2.0 | 1 |
| 197 | Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249. | 3.3 | 64 |
| 198 | Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132. | 2.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Testicular plasmacytoma: unique location or circumstantial presentation?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1769-1771. | 0.6 | 3 |
| 200 | Safety of Sedation for Patients Undergoing Bone Marrow Biopsy and Aspiration While Febrile. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 26-29. | 1.2 | 0 |
| 201 | Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77. | 1.2 | 15 |
| 202 | Unravelling hypothyroidism in ^{AL} amyloidosis: Authors' reply. <i>Journal of Internal Medicine</i> , 2018, 283, 108-108. | 2.7 | 0 |
| 203 | Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92. | 1.4 | 57 |
| 204 | Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. <i>Leukemia and Lymphoma</i> , 2018, 59, 288-299. | 0.6 | 10 |
| 205 | Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718. | 3.3 | 27 |
| 206 | Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 155-161. | 1.3 | 8 |
| 207 | Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106. | 2.8 | 16 |
| 208 | Utility and prognostic value of ¹⁸F- β FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523. | 2.0 | 19 |
| 209 | Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776. | 2.5 | 23 |
| 210 | Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018, 2, 3149-3154. | 2.5 | 23 |
| 211 | Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364. | 2.0 | 14 |
| 212 | Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2157-2159. | 2.0 | 8 |
| 213 | Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393. | 2.0 | 24 |
| 214 | Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018, 183, 421-427. | 1.2 | 37 |
| 215 | Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 304-304. | 0.6 | 10 |
| 216 | IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2018, 36, 7525-7525. | 0.8 | 6 |
| 218 | Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912. | 0.6 | 0 |
| 219 | Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). Blood, 2018, 132, 3116-3116. | 0.6 | 0 |
| 220 | Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228. | 0.6 | 0 |
| 221 | Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood, 2018, 132, 3182-3182. | 0.6 | 0 |
| 222 | Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147. | 0.6 | 0 |
| 223 | Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226. | 0.6 | 0 |
| 224 | Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. Blood, 2018, 132, 1857-1857. | 0.6 | 0 |
| 225 | Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502. | 0.6 | 0 |
| 226 | Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594. | 0.6 | 0 |
| 227 | Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227. | 0.6 | 0 |
| 228 | Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610. | 0.6 | 0 |
| 229 | Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268. | 0.6 | 0 |
| 230 | Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436. | 0.6 | 0 |
| 231 | Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884. | 0.6 | 1 |
| 232 | Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160. | 0.6 | 2 |
| 233 | Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152. | 0.6 | 1 |
| 234 | Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. Blood, 2018, 132, 719-719. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Leukemia</i> , 2017, 31, 92-99. | 3.3 | 30 |
| 236 | Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315. | 0.6 | 16 |
| 237 | Bone mineral density utilization in patients with newly diagnosed multiple myeloma. <i>Hematological Oncology</i> , 2017, 35, 703-710. | 0.8 | 8 |
| 238 | Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605. | 2.0 | 47 |
| 239 | Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551. | 1.5 | 45 |
| 240 | The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87. | 0.6 | 50 |
| 241 | Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119. | 0.6 | 249 |
| 242 | Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017, 52, 1126-1132. | 1.3 | 30 |
| 243 | Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41. | 1.4 | 4 |
| 244 | Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45. | 1.4 | 1 |
| 245 | Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619. | 2.7 | 15 |
| 246 | Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017, 31, 1562-1569. | 3.3 | 92 |
| 247 | How I treat cryoglobulinemia. <i>Blood</i> , 2017, 129, 289-298. | 0.6 | 122 |
| 248 | First report of <i>MYD88</i> ^{L265P} somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43. | 1.4 | 10 |
| 249 | Restrictive Cardiomyopathy. <i>Circulation Research</i> , 2017, 121, 819-837. | 2.0 | 219 |
| 250 | Elevation of serum lactate dehydrogenase in <i>AL</i> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895. | 1.2 | 15 |
| 251 | Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445. | 1.7 | 29 |
| 252 | Clinical trials evaluating potential therapies for light chain (AL) amyloidosis. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 655-663. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation. <i>Journal of the Neurological Sciences</i> , 2017, 379, 192-197. | 0.3 | 9 |
| 254 | High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges. <i>Leukemia and Lymphoma</i> , 2017, 58, 1283-1296. | 0.6 | 6 |
| 255 | The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017, 52, 34-40. | 1.3 | 30 |
| 256 | Importance of FISH genetics in light chain amyloidosis. <i>Oncotarget</i> , 2017, 8, 81735-81736. | 0.8 | 7 |
| 257 | Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8020-8020. | 0.8 | 0 |
| 258 | Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19532-e19532. | 0.8 | 0 |
| 259 | Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. <i>European Journal of Haematology</i> , 2016, 96, 136-143. | 1.1 | 14 |
| 260 | Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016, 51, 1449-1455. | 1.3 | 51 |
| 261 | Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016, 6, e512-e512. | 2.8 | 38 |
| 262 | Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109. | 1.7 | 9 |
| 263 | Lenalidomide – the new melphalan?. <i>Leukemia and Lymphoma</i> , 2016, 57, 1749-1750. | 0.6 | 0 |
| 264 | Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 187-195. | 1.1 | 54 |
| 265 | The Impact of Circulating Plasma Cells at Transplant on Survival in Multiple Myeloma in the Era of Novel Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S78. | 0.2 | 0 |
| 266 | Systemic Immunoglobulin Light Chain Amyloidosis – Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361. | 1.4 | 43 |
| 267 | Newer Therapies for Amyloid Cardiomyopathy. <i>Current Heart Failure Reports</i> , 2016, 13, 237-246. | 1.3 | 13 |
| 268 | Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. <i>British Journal of Haematology</i> , 2016, 172, 89-96. | 1.2 | 33 |
| 269 | First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938. | 0.6 | 17 |
| 270 | The role of stem cell transplantation in Waldenstrom's macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 229-240. | 0.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. <i>Acta Haematologica</i> , 2016, 135, 172-190. | 0.7 | 57 |
| 272 | A practical review on carfilzomib in multiple myeloma. <i>European Journal of Haematology</i> , 2016, 96, 564-577. | 1.1 | 48 |
| 273 | Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. <i>Leukemia Research</i> , 2016, 41, 56-61. | 0.4 | 7 |
| 274 | The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8033-8033. | 0.8 | 0 |
| 275 | Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8016-8016. | 0.8 | 0 |
| 276 | A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996. | 0.6 | 0 |
| 277 | Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273. | 0.6 | 0 |
| 278 | Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269. | 0.6 | 0 |
| 279 | Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. <i>Cancer Genetics</i> , 2015, 208, 575-579. | 0.2 | 12 |
| 280 | Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience. <i>Blood</i> , 2015, 126, 5386-5386. | 0.6 | 0 |
| 281 | Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study. <i>Blood</i> , 2015, 126, 5371-5371. | 0.6 | 0 |
| 282 | First line and salvage therapy with total therapy 3-based treatment for multiple myelomaâ€”An extended single center experience. <i>Leukemia Research</i> , 2014, 38, 1401-1406. | 0.4 | 10 |
| 283 | Myeloma in Scar Tissue - An Underreported Phenomenon or an Emerging Entity in the Novel Agents' Era? A Single Center Series. <i>Acta Haematologica</i> , 2014, 132, 39-44. | 0.7 | 15 |
| 284 | Surgical site infections following craniotomy focusing on possible post-operative acquisition of infection: prospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1511-1516. | 1.3 | 45 |
| 285 | The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. <i>The Cochrane Library</i> , 2013, , CD009594. | 1.5 | 17 |
| 286 | Benchmarking inappropriate empirical antibiotic treatment. <i>Clinical Microbiology and Infection</i> , 2013, 19, 629-633. | 2.8 | 23 |
| 287 | Posttransplantation Lymphoproliferative Disorder in Lung Transplant Recipients. <i>Transplantation</i> , 2013, 96, 657-663. | 0.5 | 23 |
| 288 | Post-Transplant Lymphoproliferative Disorder in Lung Transplant Recipients â€” a Shift Lo Late Onset Disease. <i>Blood</i> , 2012, 120, 5075-5075. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Persistent carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteremia in a patient with acute lymphoblastic leukemia. <i>Israel Medical Association Journal</i> , 2012, 14, 195-7. | 0.1 | 3 |
| 290 | Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4851-4863. | 1.4 | 578 |
| 291 | Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2009, 45, 3131-3148. | 1.3 | 57 |
| 292 | Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. <i>Frontiers in Endocrinology</i> , 0, 13, . | 1.5 | 0 |